Translating Innovative Ideas Into

Translating Innovative Ideas Into

IDEAYA is an oncology-focused biotechnology company committed to the discovery and development of transformative personalized medicines. We employ a translational platform based on cutting-edge technologies for discovery, validation and clinical development of biomarkers in parallel with novel therapeutics. Our biomarkers enable patient selection – identifying patients most likely to respond to a particular therapeutic, as well as target engagement – confirming that a therapeutic molecule is acting on its intended target. IDEAYA is applying its biomarker-enabled translational platform across several mechanistic approaches based on cancer biology, including targeted therapies that directly target tumor genomic susceptibilities, breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, translational biology, small molecule drug discovery, and clinical development.

Company OverviewRecent News

IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. Our people are passionate and proven cancer biologists, translational biologists, drug discovery chemists and development professionals. As an organization, we believe that our entrepreneurial spirit and nimbleness, and commitment to foster innovation, teamwork and excellence is what sets us apart. Our greatest asset is our scientists and their passion to discover innovative new therapies for cancer patients.

Yujiro S. HataIDEAYA Chief Executive Officer

Biomarker-Enabled Translational Platform

Our translational platform includes in-house capabilities coupled with strategic networks and partnerships for discovery, validation and clinical development of biomarkers – enabling technologies such as bioinformatic analysis of genomic and proteomic databases, RNA knock-down and gene editing for establishing in-vitro and in-vivo models, and tissue characterization, including liquid biopsies for identifying and characterizing circulating tumor DNA and tumor cells. Collectively, this platform creates value through patient selection and pharmacodynamic confirmation of target engagement – ultimately translating to better patient outcomes.

Learn More

Targeted Therapies

An understanding of tumor biology, in particular genomic mutations that drive cell proliferation, enables an opportunity to target oncogenic pathways for cancers with limited or no effective treatments. IDEAYA is pursuing small molecule therapeutics with step-change impact for patients with genetically defined tumors.

Learn More

Synthetic Lethality

Synthetic lethality was first suggested as a potential cancer treatment modality nearly 20 years ago and proof of concept for the approach now exists with the 2014 approval of a PARP inhibitor. IDEAYA is prosecuting a novel set of synthetic lethal drug targets through a unique, tripartite approach.

Learn More

Immuno-Oncology

Immuno-Oncology (IO) has revolutionized our ability to treat cancer. IDEAYA’s IO programs are designed to overcome the genetic and environmental factors in the tumor microenvironment (TME) that drive cancer cell evasion from both innate and adaptive immune cells.

Learn More